Geode Capital Management LLC Has $35.77 Million Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Geode Capital Management LLC decreased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 13.6% during the 4th quarter, Holdings Channel reports. The firm owned 1,576,658 shares of the life sciences company’s stock after selling 247,336 shares during the period. Geode Capital Management LLC’s holdings in Integra LifeSciences were worth $35,767,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after purchasing an additional 2,800 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth about $180,000. Romano Brothers AND Company acquired a new stake in shares of Integra LifeSciences during the 4th quarter worth about $204,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in shares of Integra LifeSciences during the 4th quarter worth about $204,000. Finally, LPL Financial LLC acquired a new position in Integra LifeSciences in the 4th quarter valued at about $255,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Down 2.1 %

Shares of NASDAQ:IART opened at $15.75 on Thursday. The business’s 50 day simple moving average is $21.69 and its 200 day simple moving average is $22.25. Integra LifeSciences Holdings Co. has a 1 year low of $15.51 and a 1 year high of $32.66. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a market capitalization of $1.22 billion, a P/E ratio of -174.98, a P/E/G ratio of 0.73 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the business earned $0.89 earnings per share. On average, research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the subject of a number of research analyst reports. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Truist Financial reduced their price target on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research note on Friday, April 11th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $22.71.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.